Abstract：Objective To investigate the clinical efficacy of valsartan / amlodipine combination and different time of taking medicine in treatment of essential hypertension. Methods 201 essential hypertensive subjects (92 men/109 women), were recruited randomized to receive valsartan(80 mg/day) and amlodipine (5 mg/day) in one of the following four therapeutic schemes: both medications on awakening, both at bedtime, either one administered on awakening and the other at bedtime. BP was measured by ambulatory monitoring for 24 consecutive hours before and after 12 wks of treatment. Results BP-lowering efficacy (quantified in terms of reduction of the 24-h mean of systolic/diastolic BP) was highest when both antihypertensive medicines were ingested at bedtime, as compared with any one of the three other tested therapeutic schemes[A(123.0±13.2)mmHg/(73.1±6.7)mmHg、B(113.6±11.0)mmHg/(67.1±8.3)mmHg、C(124.4±13.7)mmHg/(73.6±9.0)mmHg、D(119.8±13.0)mmHg/(70.6±7.2)mmHg,P<0.01]. Conclusions The greater proportion of controlled patients, improved efficacy on lowering asleep BP mean, and increased sleep-time relative BP decline suggest that valsartan/amlodipine combination therapy should be preferably administered at bedtime.
Chobanian A V,Bakris G L,Black H R,et al. Seventh report of the Joint National Committee on prevention,detection,evaluation,and treatment of high blood pressure[J]. Hypertens, 2003,42:1206-1252.
[1]
Chobanian A V,Bakris G L,Black H R,et al. Seventh report of the Joint National Committee on prevention,detection,evaluation,and treatment of high blood pressure[J]. Hypertens, 2003,42:1206-1252.
[2]
Mancia G,De Backer G,Dominiczak A,et al.2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Hypertension, 2007,25:1105-1187.
[2]
Mancia G,De Backer G,Dominiczak A,et al.2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Hypertension, 2007,25:1105-1187.
Allemann Y,Fraile B,Lambert M,et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy:the Exforge in Failure after Single Therapy (EX-FAST) study[J]. Clin Hypertens,2008,10:185-194.
[5]
Allemann Y,Fraile B,Lambert M,et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy:the Exforge in Failure after Single Therapy (EX-FAST) study[J]. Clin Hypertens,2008,10:185-194.
[6]
Brachmann J, Ansari A,Mahla G,et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy[J].Adv Ther,2008,25:399-411.
[6]
Brachmann J, Ansari A,Mahla G,et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy[J].Adv Ther,2008,25:399-411.
[7]
Liebson P R. Calcium channel blockers in the spectrum of antihypertensive agents[J]. Expert Opin Pharmacother,2003,7:2385-2401.
[7]
Liebson P R. Calcium channel blockers in the spectrum of antihypertensive agents[J]. Expert Opin Pharmacother,2003,7:2385-2401.
[8]
Miura S,Saku K.Efficacy and safety of angiotensin Ⅱ type 1 receptor blocker/calcium channel blocker combination therapy for hypertension:focus on a single-pill fixed-dose combination of valsartan and amlodipine [J].J Int Med Res ,2012,40(1):1-9.
[8]
Miura S,Saku K.Efficacy and safety of angiotensin Ⅱ type 1 receptor blocker/calcium channel blocker combination therapy for hypertension:focus on a single-pill fixed-dose combination of valsartan and amlodipine [J].J Int Med Res ,2012,40(1):1-9.
[9]
Flack J M,Calhoun D A,Satlin L,et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension:the EX-STAND study[J].Hum Hypertens,2009,23:479-489.
[9]
Flack J M,Calhoun D A,Satlin L,et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension:the EX-STAND study[J].Hum Hypertens,2009,23:479-489.
[10]
Philipp T,Smith T R,Glazer R,et al. Two multicenter,8-week,randomized, double-blind,placebo-controlled,parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension[J].Clin Ther,2007,29:563-580.
[10]
Philipp T,Smith T R,Glazer R,et al. Two multicenter,8-week,randomized, double-blind,placebo-controlled,parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension[J].Clin Ther,2007,29:563-580.
[11]
Schunkert H,Glazer R D,Wernsing M,et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy[J].Curr Med Res Opin,2009,25:2655-2662.
[12]
Sinkiewicz W,Glazer R D,Kavoliuniene A,et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy[J].Curr Med Res Opin,2009,25:315-324.
[11]
Schunkert H,Glazer R D,Wernsing M,et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy[J].Curr Med Res Opin,2009,25:2655-2662.
[13]
Koopman M G,Koomen G C,Krediet R T,et al. Circadian rhythm of glomerular filtration rate in normal individuals[J].Clin Sci (Lond),1989,77:105-111.
[12]
Sinkiewicz W,Glazer R D,Kavoliuniene A,et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy[J].Curr Med Res Opin,2009,25:315-324.
[14]
Labrecque G,Beauchamp D.Rhythms and pharmacokinetics.In Redfern P (ed.).Chronotherapeutics.London:Pharmaceutical Press,2003:75-110.
[13]
Koopman M G,Koomen G C,Krediet R T,et al. Circadian rhythm of glomerular filtration rate in normal individuals[J].Clin Sci (Lond),1989,77:105-111.
[15]
Boggia J, Li Y,Thijs L,et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study[J].Lancet,2007,370:1219-1229.
[14]
Labrecque G,Beauchamp D.Rhythms and pharmacokinetics.In Redfern P (ed.).Chronotherapeutics.London:Pharmaceutical Press,2003:75-110.
[16]
Brotman D J,Davidson M B,Boumitri M,et al. Impaired diurnal blood pressure variation and all-cause mortality[J]. Hypertens,2008,21:92-97.
[15]
Boggia J, Li Y,Thijs L,et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study[J].Lancet,2007,370:1219-1229.
[17]
Benetos A,Safar M,Rudnichi A,et al. Pulse pressure:a predictor of long-term cardiovascular mortality in a French male population.[J].Hypertension,1997,30:1410-1415.
[16]
Brotman D J,Davidson M B,Boumitri M,et al. Impaired diurnal blood pressure variation and all-cause mortality[J]. Hypertens,2008,21:92-97.
[18]
Verdecchia P,Schillaci G,Reboldi G,et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension[J].Circulation,2001,103:2579-2584.
[17]
Benetos A,Safar M,Rudnichi A,et al. Pulse pressure:a predictor of long-term cardiovascular mortality in a French male population.[J].Hypertension,1997,30:1410-1415.
[18]
Verdecchia P,Schillaci G,Reboldi G,et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension[J].Circulation,2001,103:2579-2584.
2014, Vol. 25 
